Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
- 08 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.